Welcome to our dedicated page for Natera news (Ticker: NTRA), a resource for investors and traders seeking the latest updates and insights on Natera stock.
Natera Inc (NASDAQ: NTRA) delivers cutting-edge genetic testing solutions through its proprietary molecular diagnostics platform. This news hub provides investors and healthcare professionals with timely updates on corporate developments, clinical research breakthroughs, and regulatory milestones.
Access official press releases alongside curated analysis of NTRA's innovations in non-invasive prenatal testing, oncology diagnostics, and transplant monitoring. Our repository tracks critical updates including quarterly earnings, partnership announcements, and peer-reviewed study publications.
Key coverage areas include advancements in circulating tumor DNA detection, expansions in reproductive health screening, and financial performance metrics. Bookmark this page to monitor how Natera's bioinformatics expertise continues influencing precision medicine across 150+ countries.
Natera, Inc. (NASDAQ: NTRA) has received confirmation from the Centers for Medicare & Medicaid Services (CMS) for coverage of its Signatera molecular residual disease test in patients with stage IIb or higher breast cancer. This coverage extends to all breast cancer subtypes, enhancing previous coverage for colorectal cancer and others. The decision is supported by the Exploratory Breast Lead Interval Study, showing Signatera's 89% sensitivity and 100% specificity for early relapse detection. This marks a significant milestone in precision oncology and patient care.
Natera, Inc. (NASDAQ: NTRA) has published a new paper in Pediatric Nephrology showcasing the clinical utility of its Renasight™ test for kidney disease diagnosis. The case study details a 16-year-old patient with sickle cell disease who was identified with autosomal dominant polycystic kidney disease (ADPKD) through genetic testing. This revelation emphasizes the importance of broad-panel genetic testing in managing patients with dual genetic conditions. Natera is conducting a prospective study, RenaCARE, across over 30 sites in the U.S. to further establish the test's clinical benefits.
Natera, Inc. (NASDAQ: NTRA) has announced new data on its personalized molecular residual disease (MRD) test, Signatera, set to be presented at the ASCO GI 2023 from January 19-21 in San Francisco. The presentations will showcase Signatera's effectiveness in assessing MRD across various gastrointestinal cancers, including colorectal and anal cancers. Notably, a study involving 14,425 patients suggests that MRD testing could commence as early as 2 weeks post-surgery, maintaining test sensitivity. This supports Signatera’s role in personalized cancer treatment. For further details, visit Natera’s website.
Natera, Inc. (NASDAQ: NTRA) has published a new study in Nature Medicine, highlighting the efficacy of the SignateraTM molecular residual disease (MRD) test for identifying patients with stage II-IV colorectal cancer at risk of recurrence. Data from the GALAXY arm of the CIRCULATE-Japan trial revealed that MRD-positive patients (18%) significantly benefited from adjuvant chemotherapy (ACT), while MRD-negative patients (82%) did not. The study also confirmed a pre-surgical detection rate of 95.9% for stage II-III patients, emphasizing the predictive power of Signatera in treatment decisions. This evidence builds on prior findings at ASCO GI 2022.
Natera, Inc. (NASDAQ: NTRA) announced it will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 9:45 a.m. PT (12:45 p.m. ET). Natera's management will deliver a presentation and host a Q&A session with investors. The presentation can be accessed via a live webcast on Natera's Investor Relations website, where it will also be archived for later viewing. Natera is a leader in cell-free DNA testing focused on oncology, women's health, and organ health, with a commitment to advancing personalized genetic testing.
Natera, Inc. (NASDAQ: NTRA) supports the updated guidelines from the International Society for Heart and Lung Transplantation, which recommends donor-derived cfDNA testing for heart transplant surveillance. The new guidelines advocate monthly rejection monitoring for the first six months post-transplant and again at nine and twelve months. Natera's Prospera™ Heart dd-cfDNA test, launched in late 2021, identifies allograft rejection non-invasively. The test has shown clinical validation in studies, enhancing care for heart transplant patients.
Natera, Inc. (NASDAQ: NTRA) announced a study published in JCO Precision Oncology on its ctDNA test, Signatera™, for predicting recurrence in esophageal and gastric cancers (EGCs). The real-world study involved 295 patients and 943 plasma samples. Key findings showed that pre-operative ctDNA was detectable in 96% of patients, while 23.5% post-surgery showed ctDNA presence, correlating with an 81.2% recurrence rate. Signatera proved to be the strongest prognostic factor compared to other clinicopathological factors. This underscores the test's role in better risk stratification and management of EGCs.
Natera, Inc. (NASDAQ: NTRA) will present new data at the 2022 San Antonio Breast Cancer Symposium in San Antonio, Texas, focusing on its Signatera and Empower tests. The presentations will include findings from the LEADER and I-SPY 2 clinical trials concerning breast cancer recurrence monitoring and hereditary cancer risk management. Notable highlights include two posters on December 8 and 9, showcasing the effectiveness of personalized circulating-tumor DNA testing and cell-free DNA monitoring in breast cancer management. Natera aims to provide insights for improved patient care.
Natera has published a clinical experience study showcasing its Panorama SNP-based noninvasive prenatal test (NIPT) for twin pregnancies, with findings based on 18,984 cases over 27 months. The study demonstrated a positive predictive value (PPV) of 88.7% for trisomy 21 screening, reaching 90.4% when including suggestive findings. Unique to Panorama is its ability to determine zygosity. The study corroborates earlier findings that aneuploidy rates are higher in dizygotic twins. Natera emphasizes its commitment to generating real-world evidence to enhance prenatal care.
Natera, Inc. (NASDAQ: NTRA), a leader in cell-free DNA testing, will participate in the Piper Sandler 34th Annual Healthcare Conference on November 30, 2022, at 12:00 p.m. PT (3:00 p.m. ET). CEO Steve Chapman and CFO Mike Brophy will present at the event held at the Lotte New York Palace. A live webcast of the presentation will be accessible on the Natera Investor Relations website and archived for future reference.
